The Extracellular Matrix (ECM) - the scaffolding material that organizes cells into tissues and organs - is a proactive participant in chronic disorders enabling continued inflammation, fibrosis and ischemia. Spun off from Brown University in 2022, XM Therapeutics is developing a platform technology to directly modulate the dysfunctional ECM to improve tissue function and enable organ repair. We generate injectable, acellular designer ECM Particles sourced from human 3D cell cultures. Our initial focus is on cardiovascular and pulmonary indications with significant additional potential in other diseases. We are a Providence, RI - based seed stage start-up with a clear mission: to improve the health status of patients with chronic disorders by modulating and repairing the dysfunctional Extracellular Matrix.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 225 Dyer St, Providence,rhode Island 02903,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.xmtherapeutics.com/
- Keywords
- Biotechnology, Extracellular Matrix, Biologics, Fibrosis, Heart Failure, Heart Disease, Pulmonary Fibrosis, Chronic Disorders, Technology Platform.
- HQ
- Providence, Rhode Island
Xm Therapeutics Questions
Xm Therapeutics's website is https://www.xmtherapeutics.com/
Xm Therapeutics's LinkedIn profile is https://www.linkedin.com/company/xm-therapeutics
Xm Therapeutics has
3 employees.
View email and phone details for 3
employees at Xm Therapeutics.
Xm Therapeutics's industry is
Biotechnology Research
Xm Therapeutics's top competitors are
Neuesse Inc.,
Flourish Care,
Pro Therapeutics,
Triflo Cardiovascular Inc.,
Cellbricks Therapeutics,
Asclepii,
Reconstruct Bio,
Viscus Biologics Llc,
Vascugen,
Advanced Silicon Group.
Xm Therapeutics's categories are Biotechnology Research
Xm Therapeutics's founding year is 2022
